AD/PD 2021 | Online registries allow rapid recruitment of diverse populations for AD trials

Stephen Salloway • 10 Mar 2021

AD/PD 2021

TRC-PAD

Stephen Salloway, MD, MS, Butler Hospital and Brown University, Providence, RI, discusses the importance of diverse representation in Alzheimer’s disease (AD) clinical trials in order to make substantial steps towards effective early therapy. AD and dementia do not affect all populations equally, so to understand differences in risk, outcomes, and treatment responses, broad participation in dementia research is critical. The Trial-Ready Cohort for Preclinical/prodromal Alzheimer’s Disease (TRC-PAD; NCT04004767) is an online prevention registry, addressing the need for a method of rapid recruitment for AD clinical trials. The online sign-up and remote assessments will be able to reach large numbers of participants, creating a representative trial-ready cohort. This interview took place during the AD/PD™ 2021 conference.

Disclosures

Dr. Salloway reports grants, personal fees and non-financial support from Biogen, grants and personal fees from Eisai, grants, personal free and non-financial support from Avid, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from Lilly, personal fees from Genentech, personal fees and non-financial support from Roche, outside the submitted work.